A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis

NCT01276639 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

901

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: CP-690,550
DRUG: CP-690,550
DRUG: Placebo/CP-690,550
DRUG: Placebo/CP-690,550

Sponsor

Pfizer